The effect of intravenous infusion of Corynebacterium parvum on an immune profile of women with breast cancer.
An immunological profile has been measured in 21 patients with advanced breast cancer who were treated with C. parvum (Wellcome strain CN6134). Thirteen patients received a single i.v. dose of 15 mg of C. parvum and 8 received 4 mg i.v. on 5 successive days. The "profile" was recorded before and 7-10 days after treatment and included measurement of total white count, absolute lymphocyte and monocyte counts, PHA response, B and T cell percentages. DNCB and Mantoux skin tests, immunoglobulin classes G, A, M and E and spleen size. Most patients showed a rise in white count, due largely to a polymorph leucocytosis, but there was no consistent change in any of the immunological variables recorded. IgG levels increased significantly following the single injection but not after the 5-day course; suggesting the possibility of acquired immunological tolerance. These results fail to demonstrate a consistent effect of C. parvum on either T-lymphocyte dependent function or on the spleen size, properties well documented in the experimental animal.
D001943:Breast Neoplasms / Q000276:immunology* / Q000628:therapy; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed; D007074:Immunoglobulin G / Q000032:analysis; D007136:Immunoglobulins / Q000032:analysis; D007167:Immunotherapy / Q000379:methods; D007263:Infusions, Parenteral; D011425:Propionibacterium acnes; D012882:Skin Tests
D007074:Immunoglobulin G; D007136:Immunoglobulins